---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-23-000022"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T10:32:58.281616+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Gilead Q2 revenue $6.6B (+5%); EPS down to $0.83 on $525M legal charge; guidance raised ex-Veklury

## Summary
- Total product sales ex-Veklury up 11% to $6.3B; HIV sales up 9% to $4.6B, Biktarvy up 17% to $3.0B.
- Oncology sales up 38% to $728M; Trodelvy up 63% to $260M, Cell Therapy up 27% to $469M.
- GAAP diluted EPS $0.83 vs $0.91 YoY; non-GAAP EPS $1.34 vs $1.58; impact of $0.32 from $525M HIV antitrust litigation accrual.
- Full-year 2023 guidance: total product sales raised to $26.3-26.7B (prev $26.0-26.5B); ex-Veklury raised to $24.6-25.0B; Veklury lowered to ~$1.7B (prev ~$2.0B).
- GAAP EPS guidance lowered to $4.50-4.85 (prev $4.75-5.15); non-GAAP EPS lowered to $6.45-6.80 (prev $6.60-7.00).

## SEC filing metadata
- accession: 0000882095-23-000022
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209523000022/0000882095-23-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209523000022/gild-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-23-000022
- JSON: https://secwatch.observer/filing/0000882095-23-000022.json
- Plain text: https://secwatch.observer/filing/0000882095-23-000022.txt

## Key facts
- Earnings Releases
  GILEAD SCIENCES, INC. reported the quarter ended June 30, 2023 results: revenue $6.6 billion, EPS $0.83 per share (GAAP diluted).
  - Period: the quarter ended June 30, 2023
  - Revenue: $6.6 billion
  - EPS: $0.83 per share (GAAP diluted)
  - Result: reported results
  source text: Total second quarter 2023 revenue increased 5% to $6.6 billion compared to the same period in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/882095/000088209523000022/0000882095-23-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.